Another day, another multi-billion pharma deal - the series returns!

I have to admit I was surprised to see US generic drugs giant Mylan return for Nordic group Meda given the market turbulence and general carnage in biotech share prices.

Hat tip, though, to the Financial Times for landing the scoop last night about the $9.9 billion takeover deal.